Fig. 1

Fig. 1

SPINT1 genetic alterations are associated with poor prognosis of SKCM patients. a Percentage of genetic alterations in oncogenes, tumor suppressor genes and SPINT1 in SKCM patients of the TCGA cohort (n = 479). b Survival curve of patients with genetic alteration (increased mRNA level, missense mutations and deep deletions, red line) vs. wild type (blue line) SPINT1 of SKCM of the TCGA cohort. Kaplan–Meier Gehan-Breslow-Wilcoxon and nonparametric Log-rank Test. Hazard ratio = 1.625; 95% CI of ratio = 1.099–3.033. c Genetic expression of SPINT1 in human samples from normal skin, nevus and malignant melanoma from GEO data set GDS1375 and 202826_at probe (n = 70). ***p < 0.001 according to ANOVA and Tukey’s Multiple Comparison Test. d Enrichment analysis of GO biological process. Representation of the most significant GO biological process altered when SPINT1 is affected by missense mutations or copy-number alterations. Analysis Type: PANTHER Overrepresentation Test (Released 05/12/2017), Test Type: FISHER. e Number of infiltrated macrophages and neutrophils in SKCM samples of the TCGA cohort (n = 468). The number of infiltrated cells in SKCM samples with low (blue) or high (red) SPINT1 mRNA levels according to the median. The mean ± S.E.M. for each group is shown. *p < 0.05; **p < 0.01 according to Student t Tests